All News
Aspergillus Arthritis - A Rare Opportunistic Infection
The International Osteoarticular Mycoses Consortitum has publist their review Aspergillus arthritis caused by invasive aspergillosis.
Their review identified 31 evaluable cases, 87% of whom were males and adults.
Read ArticleCPAP Use Fails to Prevent CV Events in Sleep Apnea Patients
There are numerous health hazards associated with obstructive sleep apnea (OSA), including an increased risk of cardiovascular events.
Read ArticleLupus Patients at Higher Risk for Heart Failure
Although cardiovascular disease and complications have been well-described in patients with systemic lupus erythematosus (SLE), the association between SLE and heart failure (HF) remains undefined.
Read ArticleThe RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.
Read ArticleShingles Plus Autoimmune Disease Hikes Stroke Risk
Patients with autoimmune inflammatory diseases who develop herpes zoster are at increased risk of stroke for the subsequent 3 months, with risks diminishing thereafter, analysis of Medicare data showed.
Read ArticleP. Gingivalis Antibodies Antedate Rheumatoid Arthritis Onset
Periodontal disease, gingivitis and Porphyromonas gingivalis have been linked to the pathogenesis of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPA).
Read ArticleKarolinska Scandal May Undermine the Nobel Prize
Nature reports that the Karolinska Institute and the affiliated Karolinska Hospital are being scrutinized for violations regarding stem cell research in patients without sufficient pre-clinical research, research ethics approval, or approval from regulatory authorities.
Read ArticleIs Biologic Safety Different in the Elderly?
The factors that influence the safety of biologic therapy are numerous. Amongst them, increasing age is a potential risk factor, moreso if you also consider the polypharmacy, comorbidities and longer disease duration inherent in an elderly group of rheumatoid arthritis (RA) patients.
Read ArticleAMA Policy on Freebies and Meals Clarified
A recent JAMA Internal Medicine report on pharmaceutical-sponsored meals disclosed that a $20 meal provided by a drug company could yields 2-5 times more prescriptions. (Citation source http://buff.ly/2cd58i0)
Read ArticleEMRs Causing Physician Burnout
Researchers suggest that the burden of EHRs could contribute to physician burnout. The findings of a time and motion study are published in Annals of Internal Medicine.
Read ArticleRheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read ArticleFlares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?
Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication.
The frequency of flares varies amongst studies in different populations. But the consequence of flares has only recently been studied.
Read ArticleCost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read ArticleNIH Discovers Otulipenia - New Infantile Autoinflammatory Disorder
Researchers at the National Institutes of Health, led by Dr. Dan Kastner, have led the way in the discovery and understanding of numerous autoinflammatory diseases.
Read ArticleAnother Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read ArticleHMGB1 as a Biomarker for Polymyositis and Dermatomyositis
High mobility group box chromosomal protein 1 (HMGB1) is a DNA-binding protein that functions as a structural co-factor. HMGB1 is actively secreted by macrophage/monocytes via inflammatory stimuli and is elaborated during apoptosis.
Read ArticleFDA Approves Updated Denosumab Warnings
In 2015, the Food and Drug Administration (FDA) updated the warnings of all marked bisphosphonates to include the risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read ArticleZurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read ArticleNailfold Capillaroscopy Excludes Scleroderma in Raynaud’s
Nailfold capillaroscopy test had impressive 90% negative predictive value for Systemic Sclerosis (SSc)
Read ArticleRheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article